Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
NeuroSense Therapeutics Ltd. (NRSN) had Stock-Based Compensation of $0.90M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$0.84M |
|
$0.05M |
|
$0.05M |
|
$0.90M |
|
$3.00M |
|
-- |
|
-- |
|
$3.00M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
1.84M |
|
| Cash Flow Statement Financials | |
$-1.99M |
|
$-0.01M |
|
$2.07M |
|
$0.17M |
|
$0.23M |
|
$0.07M |
|
|
Stock-Based Compensation |
$0.90M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|